Roelof Willemze

Q: What Schools Are Affiliated With Roelof Willemze

Roelof Willemze is affiliated with the following schools: University of Amsterdam, University of Eastern Piedmont, Leiden University

Roelof Willemze's AcademicInfluence.com Rankings

Roelof Willemze

Medical

#1991

World Rank

#2380

Historical Rank

Dermatology

#30

World Rank

#43

Historical Rank

medical Degrees

Roelof Willemze

Philosophy

#5853

World Rank

#8773

Historical Rank

Logic

#3063

World Rank

#4167

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Roelof Willemze's Degrees

PhD Biomedical Sciences University of Amsterdam
Masters Biomedical Sciences University of Amsterdam
Bachelors Biomedical Sciences University of Amsterdam

Why Is Roelof Willemze Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Roelof Willemze's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. (1995) (862)
Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. (2003) (782)
Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. (2006) (687)
Mesenchymal Stem Cells Inhibit Generation and Function of Both CD34+-Derived and Monocyte-Derived Dendritic Cells1 (2006) (603)
Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. (2003) (510)
Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy (1997) (488)
Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. (2002) (485)
Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia (2003) (447)
Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. (1999) (429)
Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. (2001) (382)
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. (2003) (368)
Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. (2000) (358)
Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. (1995) (282)
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. (2016) (270)
Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. (1999) (269)
Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. (1988) (268)
Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. (2001) (262)
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. (1998) (246)
The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma (2001) (246)
Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). (1999) (243)
Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. (2003) (238)
Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. (1997) (224)
Mesenchymal Stem Cells Inhibit Generation and Function of Both CD34 -Derived and Monocyte-Derived Dendritic Cells (2006) (216)
Reprogramming of Virus-specific T Cells into Leukemia-reactive T Cells Using T Cell Receptor Gene Transfer (2004) (215)
CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. (2004) (213)
KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia (2009) (209)
Mixed T cell receptor dimers harbor potentially harmful neoreactivity (2010) (207)
The clinical and histological spectrum of lymphomatoid papulosis (1982) (202)
Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. (1997) (200)
Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. (2000) (199)
Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. (2007) (186)
Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. (1996) (178)
Inhibition of human macrophage colony formation by interleukin 4 (1989) (178)
Primary extranodal and nodal non-Hodgkin's lymphoma. A survey of a population-based registry. (1989) (177)
Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice (2002) (175)
Long‐term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis (2003) (171)
The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. (2002) (170)
New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. (2004) (170)
Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. (2013) (170)
UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. (2000) (162)
Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients. (1989) (160)
Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia (1992) (159)
Cutaneous immunocytomas: a clinicopathologic study of 26 cases (1993) (157)
Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. (2003) (153)
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. (2001) (153)
The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas (1992) (152)
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. (2005) (149)
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. (2014) (147)
Minor histocompatibility antigens in human stem cell transplantation. (2003) (145)
Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe : further evidence of the role of marrow purging by mafosfamide (1991) (144)
Bcl‐2, Bcl‐6 and CD10 expression in cutaneous B‐cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance (2003) (142)
Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes (1991) (140)
Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. (1995) (139)
Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults (1988) (136)
Human fibroblasts produce granulocyte-CSF, macrophage-CSF, and granulocyte-macrophage-CSF following stimulation by interleukin-1 and poly(rI).poly(rC). (1988) (133)
Repeat polymorphisms in the interleukin-4 gene (IL4) (1991) (132)
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. (2009) (131)
Rapid mobilization of hematopoietic progenitor cells in rhesus monkeys by a single intravenous injection of interleukin-8. (1996) (127)
Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. (1997) (126)
Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity (2004) (125)
Megakaryoblastic Leukaemia (Acute Myelofibrosis): a Report of Three Cases (1979) (125)
Adolescent and adult acute lymphoblastic leukemia: prognostic features and outcome of therapy. A study of 293 patients. (1982) (124)
Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. (1996) (123)
Human Mesenchymal Stem Cells Derived from Bone Marrow Display a Better Chondrogenic Differentiation Compared with Other Sources (2007) (123)
DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. (2000) (122)
Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial (1997) (120)
Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. (1999) (119)
Primary gastrointestinal non-Hodgkin's lymphoma in a population-based registry. (1989) (116)
Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy (2009) (114)
Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene. (1992) (112)
CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior. (2001) (109)
The Treatment of Acute Myeloid Leukemia in First Relapse: A Comprehensive Review of the Literature (2002) (106)
The early phase of engraftment after murine blood cell transplantation is mediated by hematopoietic stem cells. (1998) (106)
The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients (2018) (103)
Granzyme B-expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization. (1994) (103)
Adult acute lymphoblastic leukaemia. (2004) (102)
Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. (2004) (99)
Modification of rhodamine staining allows identification of hematopoietic stem cells with preferential short-term or long-term bone marrow-repopulating ability. (1995) (97)
The influence of HLA‐matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA (1998) (97)
Cytokine production by the bladder carcinoma cell line 5637: rapid analysis of mRNA expression levels using a cDNA-PCR procedure. (1991) (96)
Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. (1997) (96)
Expression of Fas and Fas‐ligand in primary cutaneous T‐cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL (2000) (96)
KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia (2009) (95)
Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. (2007) (95)
T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. (1998) (92)
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC–HOVON randomized phase III study (06914) (2001) (92)
Presence of Epstein-Barr virus in extranodal T-cell lymphomas: differences in relation to site. (1994) (92)
Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. (1995) (90)
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). (1997) (90)
Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. (1995) (88)
Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. (2002) (87)
High dose cytosine arabinoside in the management of refractory acute leukaemia. (2009) (87)
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium (2017) (87)
αβ T-Cell Receptor Engineered γδ T Cells Mediate Effective Antileukemic Reactivity (2006) (87)
High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning. (2010) (87)
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). (2013) (86)
Interleukin 6 is a permissive factor for monocytic colony formation by human hematopoietic progenitor cells (1992) (83)
Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. (2004) (83)
HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. (1999) (81)
Biology of IL‐8‐Induced Stem Cell Mobilization (1999) (80)
Anti-LFA-1 blocking antibodies prevent mobilization of hematopoietic progenitor cells induced by interleukin-8. (1998) (79)
Clonal hematopoiesis in patients with acquired aplastic anemia. (1991) (79)
Long-term mixed chimerism after immunologic conditioning and MHC-mismatched stem-cell transplantation is dependent on NK-cell tolerance. (2005) (77)
Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. (2005) (76)
Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients <or=50 years old in first complete remission: results of the EORTC ALL-3 trial. (2004) (76)
High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. (2000) (75)
Jessner's lymphocytic infiltration of the skin. A clinical study of 100 patients. (1989) (75)
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40 (2011) (74)
Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group. (1989) (74)
Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells (2004) (74)
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial (2010) (72)
Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen. (1994) (71)
Cytotoxic T‐lymphocyte (CTL) responses against acute or chronic myeloid leukemia (1997) (70)
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia (1999) (69)
Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. (2008) (69)
Sustained engraftment of mice transplanted with IL-1-primed blood-derived stem cells. (1992) (68)
The role of metalloproteinases and adhesion molecules in interleukin-8-induced stem-cell mobilization. (2000) (68)
Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. (1989) (67)
Histopathologic studies in Sézary syndrome and erythrodermic mycosis fungoides: a comparison with benign forms of erythroderma. (1986) (67)
The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial (2003) (67)
Problems and possible solutions in finding an unrelated bone marrow donor. Results of consecutive searches for 240 Dutch patients (1997) (66)
FISH analysis of MALT lymphoma‐specific translocations and aneuploidy in primary cutaneous marginal zone lymphoma (2005) (65)
The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. (1991) (65)
Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients (2006) (64)
Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection (2010) (63)
Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath ‘in the bag’ as T-cell depletion: the Leiden experience (2006) (63)
Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia (1991) (63)
Studies on clonality by PCR analysis of the PGK-1 gene. (1991) (62)
Identification of phosphatidylinositol 4-kinase type II β as HLA class II-restricted target in graft versus leukemia reactivity (2008) (62)
Constitutive in vivo cytokine and hematopoietic growth factor gene expression in the bone marrow and peripheral blood of healthy individuals. (1995) (62)
Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors (2002) (61)
Myeloid but not lymphoid cells carry the 5q deletion: polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions. (1993) (61)
Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. (2006) (60)
Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases (2015) (60)
Interleukin 1 and poly(rI).poly(rC) induce production of granulocyte CSF, macrophage CSF, and granulocyte-macrophage CSF by human endothelial cells. (1989) (60)
Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. (2009) (60)
Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30‐positive lymphoproliferative disorders (2009) (59)
Clinical and histologic differentiation between lymphomatoid papulosis and pityriasis lichenoides. (1985) (59)
Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity. (1995) (59)
Neutrophil kinetics and the regulation of granulopoiesis. (1980) (59)
Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial (1996) (59)
Persistent clonal excess and skewed T-cell repertoire in T cells from patients with hairy cell leukemia. (1996) (58)
Serpina1 is a potent inhibitor of IL-8-induced hematopoietic stem cell mobilization (2006) (57)
Lymphomatoid papulosis in children: a study of 10 children registered by the Dutch Cutaneous Lymphoma Working Group (2001) (57)
Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. (2003) (57)
HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia (2008) (57)
Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. (1993) (56)
Differential maturation of megakaryocyte progenitor cells from cord blood and mobilized peripheral blood. (2003) (56)
Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. (2009) (55)
Immunological, cytochemical and ultrastructural studies in lymphomatoid papulosis (1983) (54)
Mantle cell lymphoma proliferates upon IL-10 in the CD40 system (2000) (54)
Langerhans cell histiocytosis first presenting in the skin in adults: frequent association with a second haematological malignancy (2012) (52)
CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications. (1995) (52)
Reduced stem cell mobilization in mice receiving antibiotic modulation of the intestinal flora: involvement of endotoxins as cofactors in mobilization. (2004) (52)
Influence of delivery on numbers of leukocytes, leukocyte subpopulations, and hematopoietic progenitor cells in human umbilical cord blood. (1994) (52)
Assessment of telomere length in hematopoietic interphase cells using in situ hybridization and digital fluorescence microscopy. (1998) (51)
Angiotropic (intravascular) large cell lymphoma of the skin previously classified as malignant angioendotheliomatosis (1987) (51)
Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study (2012) (51)
Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. (2009) (51)
Treatment of acute lymphoblastic leukemia in adolescents and a-dults: A retrospective study of 41 patients (1970-1973). (1975) (50)
Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia. (1987) (50)
Enhancement of G-CSF-induced stem cell mobilization by antibodies against the beta 2 integrins LFA-1 and Mac-1. (2002) (50)
Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. (2007) (49)
Quantitative skin cultures of Pityrosporum yeasts in patients seropositive for the human immunodeficiency virus with and without seborrheic dermatitis. (1992) (48)
Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation. (1995) (48)
Proliferation of B cell malignancies in all stages of differentiation upon stimulation in the 'CD40 system'. (1996) (48)
Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. (2002) (46)
Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. (1993) (46)
Pulmonary complications of cytosine-arabinoside therapy: radiographic findings. (1987) (46)
Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears. (1992) (45)
Functional Analysis of Killer Ig-Like Receptor-Expressing Cytomegalovirus-Specific CD8+ T Cells1 (2009) (44)
A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia: A leukemia‐lymphoma group trial of the EORTC (1986) (44)
An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice. (2002) (44)
Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group. (1999) (44)
Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application (2008) (44)
High incidence of EBV genome in CD30‐positive non‐Hodgkin's lymphomas (1992) (43)
The number of nucleated cells reflects the hematopoietic content of umbilical cord blood for transplantation (1999) (43)
Expression of killer cell inhibitory receptors is restricted to true NK cell lymphomas and a subset of intestinal enteropathy-type T cell lymphomas with a cytotoxic phenotype (2001) (42)
Effect of mast cell growth factor (c-kit ligand) on clonogenic leukemic precursor cells. (1992) (42)
Analysis of major histocompatibility antigens and the mononuclear cell infiltrate in halo nevi. (1985) (42)
α-Interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease (2004) (42)
Differential expression of the HECA‐452 antigen (cutaneous lymphocyte associated antigen, CLA) in cutaneous and non‐cutaneous T‐cell lymphomas (1992) (41)
Minor histocompatibility antigen-specific cytotoxic T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulation with HLA-identical bone marrow cells (1991) (41)
Expression of co‐stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis (2001) (41)
Stage is a better prognostic indicator than morphologic subtype in primary noncutaneous T-cell lymphoma. (1990) (41)
Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma. (2009) (39)
Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome (2001) (39)
Differential involvement of caspases in apoptosis of myeloid leukemic cells induced by chemotherapy versus growth factor withdrawal (1997) (38)
Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay (1998) (38)
Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy (2004) (37)
New concepts in the classification of cutaneous lymphomas. (1995) (37)
The many faces of lymphocytoma cutis (2003) (37)
Side effects of intermediate- and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute leukaemia and non-Hodgkin's lymphoma. (1987) (36)
The cell population of cutaneous B‐cell lymphomas (1983) (36)
High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G1 phase of the cell cycle and can be increased by interferon treatment (2003) (36)
Amsacrine with high-dose cytarabine in acute leukemia. (1985) (36)
Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine. (1993) (36)
Murine hematopoietic progenitor cells with colony-forming or radioprotective capacity lack expression of the beta 2-integrin LFA-1. (1999) (35)
Ex Vivo Expansion and Engraftment Potential of Cord Blood‐Derived CD34+ Cells in NOD/SCID Mice (2001) (34)
Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL (2014) (34)
In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients (1991) (34)
Homeostasis of telomere length rather than telomere shortening after allogeneic peripheral blood stem cell transplantation. (2003) (34)
Improved survival of lethally irradiated recipient mice transplanted with circulating progenitor cells mobilized by IL-8 after pretreatment with stem cell factor. (1996) (33)
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia (2010) (32)
Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. (2010) (32)
In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation. (1992) (31)
Mechanisms underlying hematopoietic stem cell mobilization induced by the CXC chemokine interleukin-8. (1999) (31)
Similar myeloid recovery despite superior overall engraftment in NOD/SCID mice after transplantation of human CD34+ cells from umbilical cord blood as compared to adult sources (2001) (31)
HLA-B 8 and HLA-A 3 Coexpressed With HLA-B 8 Are Associated With a Reduced Risk of the Development of Chronic Myeloid Leukemia (1999) (31)
Chemical exposures other than arsenic are probably not important risk factors for squamous cell carcinoma, basal cell carcinoma and malignant melanoma of the skin (2005) (31)
Experience with intermediate- and high-dose cytosine arabinoside in relapsed and refractory acute leukaemia. (1983) (31)
Trends of skin diseases in organ‐transplant recipients transplanted between 1966 and 2006: a cohort study with follow‐up between 1994 and 2006 (2010) (30)
Induction of CD11a/leukocyte function antigen-1 and CD54/intercellular adhesion molecule-1 on hairy cell leukemia cells is accompanied by enhanced susceptibility to T-cell but not lymphokine-activated killer-cell cytotoxicity. (1992) (30)
Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia (2002) (30)
Comparison of repopulating ability of hematopoietic progenitor cells isolated from human umbilical cord blood or bone marrow cells in NOD/SCID mice. (1998) (30)
Enhanced engraftment of umbilical cord blood-derived stem cells in NOD/SCID mice by cotransplantation of a second unrelated cord blood unit. (2005) (30)
A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL. (2010) (30)
Correction of abnormal T-cell receptor repertoire during interferon-alpha therapy in patients with hairy cell leukemia. (1998) (29)
Regulatory effects of T cell lymphokines on cytokine gene expression in monocytes. (1993) (29)
Prevalence and causative fungal species of tinea capitis among schoolchildren in Gabon (2011) (29)
The occurrence of residual or recurrent squamous cell carcinomas in organ transplant recipients after curettage and electrodesiccation (2006) (29)
Gastrointestinal complications of cytosine-arabinoside chemotherapy: findings on plain abdominal radiographs. (1990) (29)
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial (2014) (28)
T cells selectively infiltrate bone marrow areas with residual haemopoiesis of patients with acquired aplastic anaemia (1997) (28)
In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients. (1991) (28)
Mosaicism of the 5q deletion as assessed by interphase FISH is a common phenomenon in MDS and restricted to myeloid cells (1997) (28)
Diffuse cutaneous mastocytosis with multiple cutaneous mastocytomas (1980) (28)
Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia (2012) (27)
The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells. (2006) (27)
De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC). (1995) (27)
Interleukin-1 synergizes with granulocyte-macrophage colony-stimulating factor on granulocytic colony formation by intermediate production of granulocyte colony-stimulating factor. (1989) (27)
Mycosis fungoides simulating acanthosis nigricans. (1985) (27)
Proliferation of precursor B‐lineage acute lymphoblastic leukaemia by activating the CD40 antigen (1996) (26)
Proliferation of myeloid progenitor cells in human long-term bone marrow cultures is stimulated by interleukin-1 beta. (1988) (26)
Proteolytic enzyme levels are increased during granulocyte colony-stimulating factor-induced hematopoietic stem cell mobilization in human donors but do not predict the number of mobilized stem cells. (2002) (26)
Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group (2015) (26)
Magnetic resonance imaging of fetal bone marrow for quantitative definition of the human fetal stem cell compartment. (2002) (25)
In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2′-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene (1995) (25)
HLA-DPB1 mismatching results in the generation of a full repertoire of HLA-DPB1-specific CD4+ T cell responses showing immunogenicity of all HLA-DPB1 alleles. (2008) (25)
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. (2008) (25)
Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated. (2004) (25)
Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study. (1988) (25)
Early Detection and Rapid Isolation of Leukemia-Reactive Donor T Cells for Adoptive Transfer Using the IFN-γ Secretion Assay (2007) (24)
Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia. (2004) (24)
Prevalence and risk factors of inflammatory acne vulgaris in rural and urban Ghanaian schoolchildren (2009) (24)
Analysis of T‐cell clonality in bone marrow of patients with acquired aplastic anaemia (1997) (24)
Immunohistochemical studies using monoclonal antibodies on lymph nodes from patients with mycosis fungoides and Sézary's syndrome. (1985) (23)
Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning (2007) (23)
Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group (2010) (23)
TOX expression in cutaneous T‐cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4+ CD8− phenotype (2016) (23)
Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon. (1996) (23)
Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells. (2009) (23)
Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria (2006) (23)
Impaired expression of CD28 on T cells in hairy cell leukemia. (1999) (23)
Palmar-plantar skin changes and cytarabine. (1985) (22)
Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial (2006) (22)
Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins. (2004) (22)
The role of cytokines and hematopoietic growth factors in the autocrine/paracrine regulation of inducible hematopoiesis (1997) (22)
The role of interleukin-1 in hematopoiesis. (1991) (22)
Results of induction and consolidation treatment with intermediate and high‐dose cytosine arabinoside and m‐Amsa of patients with poor‐risk acute myelogeneous leukaemia (1988) (22)
Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. (2004) (22)
Long‐term follow‐up of recipients of allogeneic bone marrow grafts reveals no progressive telomere shortening and provides no evidence for haematopoietic stem cell exhaustion (2002) (22)
Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT). (2002) (22)
Both permissive and nonpermissive HLA-DPB1 mismatches can induce polyclonal HLA-DPB1 specific immune responses in vivo and in vitro. (2010) (22)
Continuous infusion of interleukin-6 in sublethally irradiated mice accelerates platelet reconstitution and the recovery of myeloid but not of megakaryocytic progenitor cells in bone marrow. (1993) (22)
Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia (2006) (22)
Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. (1988) (21)
Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia (2011) (21)
Interleukin-6 is not involved in the interleukin-1-induced production of colony-stimulating factors by human bone marrow stromal cells and fibroblasts. (1989) (21)
Profiling of apoptosis genes identifies distinct types of primary cutaneous large B cell lymphoma (2008) (21)
High-dose cytosine arabinoside: pharmacological and clinical aspects (2004) (21)
Varicella zoster virus (VZV)-related progressive outer retinal necrosis (PORN) after allogeneic stem cell transplantation (2005) (20)
Abnormally activated T lymphocytes in the spleen of patients with hairy-cell leukemia. (1994) (20)
A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC. (1997) (19)
Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis (2019) (19)
Hairy cell leukemia-specific recognition by multiple autologous HLA-DQ or DP-restricted T-cell clones. (1999) (19)
Interleukin 6 Is a Permissive Factor for Monocytic Colony Fogmation by Human Hematopoietic Progenitor Cells By J. H. Jansen,* J. C. Kluin-Nelemans,* J. Van Damme,~ (1992) (19)
Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells. (1990) (19)
Intermediate and high-dose cytosine arabinoside-containing regimens for induction and consolidation therapy for patients with acute lymphoblastic leukemia and lymphoblastic non-Hodgkin's lymphoma: the Leyden experience and review of the literature. (1987) (19)
Assignment of the human deoxycytidine kinase (DCK) gene to chromosome 4 band q13.3-q21.1. (1993) (19)
Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay. (2007) (19)
Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia. (2005) (19)
Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin (2003) (18)
A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia (1992) (18)
Colony growth of human hematopoietic progenitor cells in the absence of serum is supported by a proteinase inhibitor identified as antileukoproteinase (1996) (18)
Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft (‘Campath in the bag’) (2009) (18)
Interleukin-10, interleukin-12, and tumor necrosis factor-α differentially influence the proliferation of human CD8+ and CD4+ T-cell clones (1996) (18)
The diagnostic value of morphometry on blood lymphocytes in erythrodermic actinic reticuloid. (1995) (18)
Identification of Varicella-Zoster Virus-Specific CD8 T Cells in Patients after T-Cell-Depleted Allogeneic Stem Cell Transplantation (2009) (18)
Short‐term intensive treatment (V.A.A.P.) of adult acute lymphoblastic leukemia and lymphoblastic lymphoma (1988) (18)
Differential activation of the death receptor pathway in human target cells induced by cytotoxic T lymphocytes showing different kinetics of killing (2007) (18)
Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer. (2000) (17)
Production of tumor necrosis factor-alpha by normal and malignant B lymphocytes in response to interferon-alpha, interferon-gamma and interleukin-4. (1992) (17)
Randomised placebo controlled study of RH-GM-CSF following ALG in the treatment of aplastic anaemia. (1991) (17)
Is mycosis fungoides exacerbated by fluoxetine? (1996) (17)
Erythema and swelling of ears after treatment with cytarabine for leukemia. (1990) (16)
Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission (2008) (16)
Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway (1992) (16)
Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines. (2003) (16)
Neutropenic enterocolitis following treatment with cytosine arabinoside-containing regimens for hematological malignancies: A potentiating role for amsacrine (1991) (15)
Deoxycytidine kinase, thymidine kinase and cytidine deaminase and the formation of Ara-CTP in leukemic cells in different phases of the cell cycle. (1990) (15)
A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia (1992) (15)
The biological activities of interleukin-1 (1989) (15)
Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells (2006) (15)
Differences in Epstein-Barr virus expression between primary and secondary cutaneous angiocentric lymphomas. French Study Group of Cutaneous Lymphomas. (1998) (15)
Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms. (1990) (15)
Involvement of the complement system in the pathogenesis of pulmonary leukostasis in experimental myelocytic leukemia. (1993) (15)
The hematopoietic activities of interleukin-1 (1989) (15)
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study (2014) (14)
Detailed Analysis of IFNg Response Upon Activation Permits Efficient Isolation of Cytomegalovirus-specific CD8+ T Cells for Adoptive Immunotherapy (2009) (14)
Cisplatin (P), vinblastine (V), and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa cell tumor of the ovary (GCTO): An eortc gynecology cancer cooperative group study (1989) (14)
Neurological complications in patients with cutaneous T‐cell lymphoma (1986) (14)
Primary cutaneous B-cell lymphomas. (1994) (14)
Marrow culture in diffusion chambers in rabbits. I. Effect of mature granulocytes on cell production. (1978) (14)
A retrospective Dutch study comparing T cell-depleted allogeneic blood stem cell transplantation vs T cell-depleted allogeneic bone marrow transplantation. (1998) (13)
Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia. (2005) (13)
Multiple minor histocompatibility antigen disparities between a recipient and four HLA-identical potential sibling donors for bone marrow transplantation. (1993) (13)
Fournier's gangrene or fulminant necrotizing fasciitis of the scrotum and penis as a complication of granulocytopenia in a patient with acute myelogenous leukaemia (AML). (1988) (13)
Systemic polychemotherapy in patients with mycosis fungoides and lymph node involvement: a follow-up study of 17 patients. (1985) (13)
Absence of mutations in the RET gene in acute myeloid leukemia (1997) (13)
Cytokine‐Dependent Proliferation of Human CD34+ Progenitor Cells in the Absence of Serum Is Suppressed by Their Progeny's Production of Serine Proteinases (2006) (13)
Human interleukin for DA cells (HILDA) does not affect the proliferation and differentiation of hematopoietic progenitor cells in human long-term bone marrow cultures. (1992) (12)
New techniques in the evaluation of cutaneous T-cell lymphoma. (1985) (12)
The human interleukin-6 receptor α chain gene is localized on chromosome 1 band q21 (2004) (12)
Factors influencing release of granulocyte‐macrophage colony‐stimulating activity from human mononuclear phagocytes * (1988) (12)
Incidence of mycosis fungoides and Sézary syndrome in the Netherlands between 2000 and 2020 (2021) (12)
Autologous versus allogeneic stem cell transplantation in acute myeloid leukemia. (2004) (12)
Percentage of S-phase cells in bone marrow aspirates, biopsy specimens and bone marrow aspirates corrected for blood dilution from patients with acute leukemia. (1987) (12)
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase III study (2020) (12)
Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients (2020) (12)
High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT (2015) (12)
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013) (2015) (12)
TREATMENT OF REFRACTORY ACUTE LEUKAEMIA WITH HIGH DOSE CYTOSINE ARABINOSIDE (1982) (11)
Repeated hematopoietic stem and progenitor cell mobilization without depletion of the bone marrow stem and progenitor cell pool in mice after repeated administration of recombinant murine G-CSF. (2007) (11)
Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype (2018) (11)
The human interleukin-6 receptor alpha chain gene is localized on chromosome 1 band q21. (1993) (11)
Suppression of retrovirial replication: inactivation of murine leukemia virus by compounds reacting with the zinc finger in the viral nucleocapsid protein. (1997) (11)
Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia. (1986) (11)
Haemopoietic growth factor tyrosine kinase receptor expression profiles in normal haemopoiesis (1996) (11)
Results of induction and consolidation treatment with intermediate and high-dose ara-C and m-AMSA containing regimens in patients with primarily failed or relapsed acute leukemia and non-Hodgkin's lymphoma. (2009) (11)
High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma (1995) (11)
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies (2014) (11)
Identification of four new HLA-DR restricted minor histocompatibility antigens as hematopoietic targets in anti-tumor immunity (2009) (10)
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. (2019) (10)
Marrow culture in diffusion chambers in rabbits: III. Effect of endotoxin and leukocyte products on cell production (1979) (10)
High Dose Intensive Chemotherapy, as Is Standard in Childhood Leukemia, Is Feasible and Efficacious in Adult Patients with Acute Lymphoblastic Leukemia (ALL) up to the Age of 40 (2009) (10)
Point and period prevalences of eczema in rural and urban schoolchildren in Ghana, Gabon and Rwanda (2012) (10)
Long-term follow-up of recipients of allogeneic bone marrow grafts reveals no progressive telomere shortening and provides no evidence for haematopoietic stem cell exhaustion (2002) (10)
Primary Allogeneic T-Cell Responses against Mantle Cell Lymphoma Antigen-Presenting Cells for Adoptive Immunotherapy after Stem Cell Transplantation (2005) (10)
The role of the CD40 antigen on malignant B cells. (1996) (9)
Correction of neutropenia associated with chronic lymphocytic leukaemia following treatment with granulocyte-macrophage colony-stimulating factor (1991) (9)
Hairy cell leukemia: in-vitro proliferation and pseudo-colony formation. (1987) (9)
Accelerated platelet reconstitution following transplantation of bone marrow cells derived from IL-6-treated donor mice (1996) (9)
Dinucleotide repeat polymorphism in the interferon regulating factor 1 (IRF1) gene. (1993) (9)
Inhibitory effect of interleukin-4 on the proliferation of acute myeloid leukemia cells with myelo-monocytic differentiation (AML-M4/M5); the role of interleukin-6. (1993) (9)
Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL (2014) (9)
8-Bromo-cAMP induces a proliferative response in an IL-3 dependent leukemic cell line and activates Erk 1,2 via a Shc-independent pathway. (1997) (9)
IL-4 down-regulates IL-2-, IL-3-, and GM-CSF-induced cytokine gene expression in peripheral blood monocytes (1994) (8)
Interleukin 4 down-regulates the expression of CD14 and the production of interleukin 6 in acute myeloid leukemia cells. (1991) (8)
Development of pulmonary leukostasis in experimental myelocytic leukemia in the Brown-Norway rat. (1992) (8)
B-cell colony growth of malignant and normal B-cells. (1987) (8)
A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group. (1992) (8)
Allogeneic vs autologous stem cell transplantation according to cytogenetic features in AML patients (pts) <= 45 yrs old in first CR: Results of the EORTC-GIMEMA AML-10 trial (2001) (8)
A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group. (1990) (8)
A simplified assay for measurement of cytosine arabinoside incorporation into DNA in Ara-C-sensitive and-resistant leukemic cells (2004) (7)
Allogeneic versus autologous bone marrox transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A) (1992) (7)
Haematopoietic growth factors. (1989) (7)
Aleukaemic leukaemia cutis in a patient with acute T‐cell lymphoblastic leukaemia (2003) (7)
Unconventional rapid ERK1,2 activation is indispensable for proliferation of the growth factor-independent myeloid leukemic cell line KG1 (1998) (7)
Relative value of allogeneic BMT, autologous BMT and intensive chemotherapy during the first complete remission (CR) of acute myelogenous leukemia (AML). An interim analysis of the AML8 EORTC-GIMEMA protocol. (1990) (7)
Barge The mechanisms of AraC-induced apoptosis of resting B-chronic lymphocytic leukemia cells (2006) (7)
The morphology of dyserythropoiesis in a patient with acute erythroleukaemia associated with multiple myeloma. (2009) (7)
Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A). The EORTC Leukemia Cooperative Group and the GIMEMA Group. (1992) (7)
Leukemia Inhibitory Factor Induces In Vivo Expansion of Bone Marrow Progenitor Cells that Accelerate Hematopoietic Reconstitution but Do Not Enhance Radioprotection in Lethally Irradiated Mice (1997) (7)
The revised European-American lymphoma (REAL) classification of non-Hodgkin's lymphoma: a missed opportunity? (1995) (7)
Engraftment potential into NOD/SCID mice of CD34+ cells derived from human fetal liver as compared to fetal bone marrow. (2001) (6)
Marrow culture in diffusion chambers in rabbits. II. Effect of competing demands for red cell and white cell production on cell growth. (1978) (6)
Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials (2020) (6)
Day-6 bone marrow aspirate for the prediction of response to remission induction therapy for acute myelogenous leukaemia (1988) (6)
XV. Primary cutaneous lymphomas (2011) (6)
A novel RT-PCR-based protein activity truncation assay for direct assessment of deoxycytidine kinase in small numbers of purified leukemic cells (2000) (6)
Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria: An on Going Joint Study of the AAWP EBMT Group and the French Society of Hematology (2008) (6)
Differential stimulatory and inhibitory effects of interleukin 4 on granulocytic and monocytic colony formation in human bone marrow cultures. (1991) (6)
Activity of 5 Aza-2-Deoxycytidine in Ara-C Resistant and Sensitive Leukemia (1989) (6)
Experience with intermediate and high dose cytosine arabinoside in refractory acute leukaemia. (1983) (5)
Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF) (1992) (5)
A comparison of two culture techniques: an in vitro & an in vivo tumour colony-forming assay. (1985) (5)
Comparable engraftment and chimerism kinetics using oral and intravenous fludarabine as part of a reduced intensity conditioning regimen (2008) (5)
Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial (2016) (5)
Cloning of the Dck gene encoding rat deoxycytidine kinase. (1994) (5)
Direct display of hematopoietic tyrosine kinase receptor expression profiles in KG1 cells by PCR using degenerate primers. (1996) (5)
Deoxycoformycin in therapy of refractory lymphoid neoplasms. (1988) (5)
Up-Front Window Trial of Gemtuzumab Ozogamicin (GO) in Previously Untreated Elderly Patients with AML: An EORTC Leukemia Group Study. (2004) (5)
Separation, enrichment, and characterization of human hematopoietic progenitor cells from umbilical cord blood (1993) (5)
AB T-Cell Receptor Engineered ; D T Cells Mediate Effective Antileukemic Reactivity (2006) (5)
Order of human hematopoietic growth factor and receptor genes on the long arm of chromosome 5, as determined by fluorescence in situ hybridization (2005) (5)
Treatment of patients with acute promyelocytic leukemia. The EORTC-LCG experience. EORTC Leukemia Cooperative Group. (1994) (5)
Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROCLIPI international Study. (2020) (5)
The antileukaemic activity of 5-Aza-2-deoxycytidine (Aza-dC) in patients with relapsed acute leukaemia. (1989) (5)
Selective response of CD5+ B cell malignancies to activation of the CD72 antigen. (1998) (4)
Extramedullary hematopoietic growth factor and cytokine gene expression indicate endocrine regulation of hematopoiesis in patients with acute appendicitis (1997) (4)
Comparison of intensive consolidation therapy and autologous bone marrow transplantation in acute myeloid leukaemia. The Leiden experience. (1989) (4)
Bone marrow transplantation or chemotherapy as post-remission treatment of adult acute myelogenous leukemia (1991) (4)
Stem cell transplantation in ALL : a donor versus no donor comparison in the EORTC ALL-4 study (2007) (4)
Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm (2019) (4)
An Evaluation of Host Cell Contact in the Regulation of Diffusion Chamber Hematopoiesis (1980) (4)
Unrelated bone marrow transplantation as a rescue procedure following inadvertent loss of an autologous bone marrow graft. (1996) (4)
Detection of partial cDNA sequences differentially expressed in patients with myelodysplasia (1996) (4)
Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON leukemia group trials (2013) (4)
Interleukin-9 stimulates the proliferation of enriched human erythroid progenitor cells: additive effect with GM-CSF (2005) (4)
Hairy cell leukemia (1987) (4)
Sequential administration of gemtuzubab ozogamicin (GO) and intensive chemotherapy for remission induction in previously untreated patients with AML over the age of 60: Interim results of the EORTC leukemia group AML-15A phase II trial (2001) (4)
High-Dose Therapy in AL Amyloidosis : A Prospective Phase II Study by the Dutch-Belgian Cooperative Group (HOVON) (2008) (4)
IL-31 Receptor Alpha Expression in Epidermal Keratinocytes Is Modulated by Cell Differentiation and Interferon Gamma (2009) (4)
Should primary cutaneous Ki-1(CD30)-positive anaplastic large cell lymphoma in childhood be treated with multiple-agent chemotherapy? (2001) (4)
Preliminary results of consolidation therapy with high-dose cytosine arabinoside for patients with bad-risk or relapsed acute leukemia or lymphoblastic non-Hodgkin's lymphoma. (1987) (4)
Experimental myelocytic leukemia in the Brown-Norway rat as a model for pulmonary leukostasis. (1991) (4)
In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML). (1985) (4)
Interleukin-4 (1990) (4)
The unrelated bone marrow donor. (1988) (4)
Fludarabine vs. High dose continuous chlorambucil : Interim analysis of a randomized phase II study in untreated B-cell chronic lymphocytic leukemia (B-CLL) (1996) (4)
Stem cells with short-term and long-term repopulating ability in the mouse. (1996) (4)
Treatment with Tyrosine Kinase Inhibitors May Impair the Potential Curative Effect of Allogeneic Stem Cell Transplantation. (2009) (3)
TCRγδ+ cells expressing Vγ 9Vδ 2, which normally predominate the blood, are found in the spleens of patients with hairy cell leukemia (1997) (3)
Human T Cells with Distinct Specificities Mediate Graft-Versus-Leukemia Reactivity and Xenogeneic Graft-Versus-Host Disease in a NOD/Scid Mouse Model for Human Acute Leukemia. (2009) (3)
Quantitation of tumour development correlates with prognosis in tumour stage (stage IIB) mycosis fungoides (2014) (3)
Biology and treatment of myelodysplastic syndromes — developments in the past decade (1993) (3)
Serum monocyte colony-stimulating factor, erythropoietin and interleukin-6 in relation to pancytopenia in hairy cell leukemia. (1992) (3)
Cytarabine and CNS toxicity. (1992) (3)
No expression of LFA-1 on murine hematopoietic progenitor cells with colony-forming or radioprotective capacity (1997) (3)
Donor Lymphocyte Infusion (DLI) for Mixed Chimerism 6 Months after T Cell Depleted Allogeneic Stem Cell Transplantation (TCD alloSCT) May Prevent Relapse. (2006) (3)
Monoclonal proteinaemia and solid tumours. (2004) (3)
Allogeneic vs autologous stem cell transplantation according to cytogenetic and FAB features in AML patients (pts) <=45 yrs old in CRI: Results of the EORTC-GIMEMA AML-10 trial (2002) (3)
Comparison of quality of life (QOL) of patients with acute myelogenous leukemias (AML) in long-term first complete remission (CR) after bone marrow transplantation (BMT) - Allogeneic or autologous - Or intensive chemotherapy consolidation (ICC): EORTC-GIMEMA AML 8A study (1995) (3)
Developing a European network for adult ALL. (2004) (3)
Primary lymphoblastic non‐Hodgkin's lymphoma of the skin (1981) (3)
E‐rosette positive acute lymphoblastic leukaemia in adolescents and adults (1983) (3)
Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials (2018) (3)
Array CGH and COBRA-FISH reveal recurrent genetic alterations in Sezary syndrome (2006) (3)
Extranodal non-Hodgkin's lymphoma. (1988) (2)
Mesenchymal Stem Cells Inhibit Generation and Function of Both Monocyte-Derived and CD34-Derived Dendritic Cells. (2005) (2)
New drugs in acute myeloid leukemia (2014) (2)
C11) Clonality of hematopoiesis in patients with aplastic anemia and myelodysplastic syndromes (1991) (2)
Gall bladder perforation in response to chemotherapy in a patient with a histiocytic lymphoma. (1988) (2)
Induction and consolidation treatment with intermediate (IDARAC) and high-dose Ara-C (HDARAC) and m-AMSA in patients (pts) with primarily failed or relapsed acute leukaemia and high-grade non-Hodgkin's lymphoma (NHL) (1986) (2)
Efficient Induction and Isolation of CMV-Specific CD8+ T Cells from CMV Seronegative Donors for the Treatment of CMV Reactivation in CMV Seropositive Patients Transplanted with a CMV Seronegative Donor. (2007) (2)
Recent developments in the early diagnosis of mycosis fungoides and Sézary's syndrome. (1987) (2)
Sublocalization of the breakpoints of a t(5;16) in myelodysplasia. (1998) (2)
Vigorous Priming of Minor Histocompatibility Antigen Specific T Cells by Frequent High Dose Peptide Vaccination May Lead to Prolonged T Cell Receptor Downregulation, Impaired T Cell Functionality, and Promotion of Tumor Escape. (2007) (2)
Proliferation of hematopoietic progenitor cells in long-term bone-marrow cultures (ltbmc) and the release of colony-stimulating factors (csfs) by human stromal cells is stimulated by interleukin-1-beta (il-1) (1988) (2)
GM-CSF and IL-3 in Myelodysplastic Syndromes at Low Risk of Developing Acute Leukemia (MDS-LR) (1992) (2)
Treatment of acute myelogenous leukaemia in adults. A retrospective study of 70 patients (1968-1973). (1975) (2)
Human Alloreactive CD4+ T Cells as Potent Effector Cells and Sole Mediators of Anti-Tumor Responses in a NOD/SCID Mouse Model for Human Acute Leukemia. (2008) (2)
Rituximab and Alemtuzumab in Combination, but Not Alone, Induce Complete Remissions in a Preclinical Animal Model of Primary Human ALL: Rationale for Combination Treatment. (2007) (2)
Absence of loss of heterozygosity of the IRF1 gene in some patients with a 5q31 deletion. (1994) (2)
Presence of Epstein-Barr Viral DNA and EBV Latent Gene Products in Hodgkin and Non-Hodgkin Lymphoma: High Expression of EBV-DNA Sequences in Non-Hodgkin Lymphoma with Variable Numbers Of CD30-Positive Cells (1994) (2)
Cell kinetics after high dose cytosine arabinoside in patients with acute myelocytic leukemia (1990) (2)
[Comparison between intensive consolidation by bone marrow autograft or by chemotherapy of acute myeloblastic leukemias in 1st complete remission: AML8A protocol of the Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC)]. (1993) (2)
New trends in the treatment of adult acute myeloid leukaemia (1997) (2)
EORTC-GIMEMA AML8 protocol. A phase III study on autologous bone-marrow transplantation in acute myelogenous leukemia (AML). (1994) (2)
Clofarabine in combination with a standard remission induction regimen in patients 18-60 years old previously untreated intermediate an bad risk actue myelogenous leukemia (AML) or high risk myelodysplasia (MDS): combined phase I/II results of the EORTC/Gimema AML-14A trial (2014) (1)
Outcomes of Unrelated Cord Blood Transplantation for Non-Malignant Diseases in Children Are Not Associated with KIR-Ligand Matching Between Donor and Recipient: a Study On Behalf of Eurocord. (2009) (1)
Patients with aplastic anemia (AA) before or after treatment with anti-thymocyte globulin (ATG) may exhibit clonal hematopoiesis. (1991) (1)
Pentostatin (2'-deoxycoformycin) for the treatment of lymphoid neoplasms. (1990) (1)
YNK01, an Oral Cytosine Arabinoside Derivative in Acute Myeloid Leukemia and Chronic Myeloid Leukemia (1997) (1)
Dexamethasone Versus Methyl-Prednisolone in Induction Therapy for Adult Acute Lymphoblastic (ALL) and Non-Hodgkin Lymphoma (NHL) Patients ≤ 60 Yrs Old: Final Results of the Eortc All-4 Phase III Trial. (2005) (1)
Mechanisms of stem cell mobilization in mice (1997) (1)
Recombination of Endogenous TCR Chains with Retrovirally Introduced TCR Chains Can Result in Mixed T Cell Receptor Dimers Harbouring Harmful Alloreactivity (2008) (1)
C ombined MV-trans Retinoic Acid and Idarubicin (AIDA) Therapy (1997) (1)
Adoptive Immunotherapy with Donor Lymphocyte Infusions after T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia. (2005) (1)
Hematopoietic Chimerism Following Non-Myeoloablative Stem Cell Transplantation Is Dependent on NK Cell Tolerance. (2004) (1)
Sequence Dependent Efficiency of Cross-Presentation in MHC Class I Requires Rational Design of Long Synthetic Peptides for Vaccination or Ex Vivo Activation (2008) (1)
Mechanisms of stem cell mobilization (1997) (1)
Donor Lymphocyte Infusion for Mixed Chimerism or Residual Disease after Reduced-Intensity T Cell Depleted Stem Cell Transplantation Results in Conversion to Full Donor Chimerism Combined with Graft Versus Tumor Responses and Limited GVHD. (2007) (1)
Incidence and Clinical Impact of TET2 Mutations in Acute Myeloid Leukemia Patients Treated within the EORTC/GIMEMA AML-12/06991 AML Trial. (2009) (1)
Upregulation of CD20 on Human Acute Lymphoblastic Leukemia Cells by IL-4 and CpG Motif Containing Oligonucleotides Increases Susceptibility to Rituximab. (2006) (1)
Marrow Culture in Diffusion Chambers in Rabbits IV. Effects of Leukocyte Products on Granulopoiesis (1980) (1)
[Chimerism pattern following allogeneic bone marrow transplantation; a retrospective study of the connection with post-transplantation complications]. (1990) (1)
Tumor necrosis factor alpha (Tnf-α) Production by acute myeloid leukemic (Aml) Blasts results in impaired proliferation of normal hematopoietic progenitor cells (Hpc) (2000) (1)
The Prodrug AQ4N Displays Potent Anti-Tumor Activity in a Xenotransplantation Model of Primary Human Acute Lymphoblastic Leukemia. (2005) (1)
Radioresistant pseudo-colony formation in the PHA-leukocyte feeder colony assay. (1988) (1)
SHORT‐TERM HIGH‐DOSE TREATMENT IN BAD‐RISK ALL AND LYMPHOBLASTIC NHL (1987) (1)
71 Clonality of hematopoiesis in myelodysplasia (1997) (1)
Lymphomatoid papulosis: its relationship with mycosis fungoides and Hodgkin's disease (1984) (1)
Marrow Culture in Diffusion Chambers in Rabbits (2005) (1)
Lifting a tip of the veil of human minor Histocompatibility antigens. (1995) (1)
Allogeneic SCT planned in CR-1 after intensive chemotherapy in patients with bad prognosis MDS results in better outcome in the intermediate/high-risk cytogenetic group: a study by the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups (2006) (1)
High Dose (HD-AraC) vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction in Acute Myelogenous Leukemia (AML): Impact on Stem Cell Mobilization after Consolidation and on Autologous Transplantation (Second Report of the EORTC-Leukemia Group (LG) - GIMEMA AML-12 Trial. (2006) (1)
Autologous stem cell transplantations in elderly AML patients (1996) (1)
Intensification of GVHD prophylaxis interferes with the effects of pretransplant herpes virus serology on the occurrence of grades II–IV acute graft-versus-host disease (2005) (1)
Chromosome 3q abnormalities in 43 untreated AML patients aged 15-60 years: preliminary results of the randomized AML-10 phase III trial of the EORTC and GIMEMA Leukemia Groups (2001) (1)
Antibodies to the beta 2-integrins LFA-1 and Mac-1 synergistically enhance stem cell mobilization induced by G-CSF (1999) (1)
OP08 High dose (HD-AraC) vs standard dose cytosine arabinoside (SD-AraC) during induction in acute myelogenous leukemia (AML): Impact on stem cell mobilization after consolidation and on autologous transplantation (AML-12 trial) (2007) (1)
Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk mds and secondary aml treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups (2001) (1)
The in vivo diffusion chamber technique for bone marrow or blood cell culture (1981) (1)
[Treatment of acute myelogenous leukemia in adults; an account of the years 1968 to 1975]. (1977) (1)
An in vivo clonogenic assay for human tumors using plasma clot diffusion chambers implanted in mice. (1985) (1)
[Acute lymphatic leukemia in adolescents and adults: treatment results in 75 patients during 1970--1977]. (1979) (1)
Results of a multicentre study of the treatment of acute lymphoblastic leukaemia in adolescents and adults (1978-1981). (1982) (1)
Comprehensive promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma (2013) (1)
The human macrophage colony-stimulating factor gene is localized at chromosome 1 band p21 and not at 5q33.1 (1992) (1)
372: Leukemic Blasts Acting as Host Antigen Presenting Cells Trigger a Combined CD4 and CD8 Allo-Immune Response Directed against Mismatched HLA Class I (2008) (1)
Primary “Reticulum Cell Sarcoma” of the Skin:High Frequency of True Histiocytic Lymphoma (Histiocytic Sarcoma) (1982) (1)
The Effect of Donor Lymphocyte Infusion Dose on the Occurrence of Severe Life-Threatening Acute Graft-Versus-Host Disease Early after Reduced Intensity Conditioning T Cell Depleted Stem Cell Transplantation. (2008) (1)
P-18 A new prognostic score foroutcome of patients with high-risk myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (SAML) after intensive antileukemic treatment (2005) (1)
O07 Dexamethasone versus methyl-prednisolone for adult acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma (NHL) in patients ≤60 yrs old: final results of the EORTC ALL-4 Phase III Trial (2007) (1)
(EBMT) study of the European Group for Blood and Marrow Transplantation Hematopoietic stem cell transplantation for de novo erythroleukemia: a (2013) (0)
interferon-responsive (ADIR) gene minor histocompatibility antigen encoded by the ATP-dependent reactive T cells recognize an activation-induced - Multiple myeloma (2013) (0)
High Levels of Circulating Hematopoietic Progenitor Cells after Continuous Infusion of High Dose Interleukin-2 in Cancer Patients (1991) (0)
PP64. Resource utilisation in intensive chemotherapy, autologous versus allogeneic bone marrow transplantation in acute myeloid leukemia (1997) (0)
Post remission treatment in acute myelogenous leukaemia in first remission. The EORTC experience. EORTC Leukemia Cooperative Group. (1989) (0)
Colony growth of human hematopoietic progenitor cells in the absence of serum is supported by antileukoproteinase (ALP) (1995) (0)
In Vitro Cell Division Analysis Reveals High Proliferative Potential and Clonogenicity within Primary Common-Type Human Acute Lymphoblastic Leukemia. (2005) (0)
Postremission Therapy: The Role of Allogeneic Bone Marrow Transplantation in Acute Myelogenous Leukemia: An Analysis of the AML8A EORTC-GIMEMA Protocol (1997) (0)
Biology of Stem Cell Mobilization Induced by Cytokines (2003) (0)
Intensive chemotherpay versus autologous stem cell transplantation (ASCT) for the treatment of patients with poor risk MDS and secondary AML (sAML) (2000) (0)
Proliferation of Acute Lymphoblastic Leukemic (ALL) Cells Is Dependent on Exogenous Purine Administration. (2007) (0)
Particle-bound DNA polymerase activity in haematological disorders and normal controls (2004) (0)
Validation of WHO-EORTC classification for primary cutaneous diffuse large B-cell lymphoma and characterization of diagnostic and prognostic markers (2006) (0)
Treatment of Acute Lymphoblastic Leukaemia in Adolescents and Adults (2009) (0)
A Two Step Nonmyeloablative Allogeneic Transplantation Protocol Using In Vitro T-Cell Depleted Mobilized Stem Cells Followed by Donor Lymphocyte Infusions in Patients with Advanced CLL. (2005) (0)
Identification and characterization of murine stem cells with preferential short-term or long-term bone marrow repopulating ability (1995) (0)
Detection of Varicella Zoster Virus Specific CD8 T Cells in Patients after T Cell Depleted Allogeneic Stem Cell Transplantation by a Novel Epitope Screening Technology. (2007) (0)
Generation of autologous leukemia-reactive CD4+ T cell lines from a hairy cell leukemia (HCL) patient (1997) (0)
Expansion and Transformation of Primary Acute Lymphoblastic Leukemia Cells into Antigen-Presenting Cells using a Novel Culturing System Enables the Generation of Leukemia-Reactive T Cell Responses that Are Effective in Vivo. (2004) (0)
Normalization of skewed T cell repertoire by interferon-α therapy in patients with hairy cell leukemia (1997) (0)
Increased Engraftment after Double Cord Blood Transplantation in NOD/SCID Mice. (2004) (0)
Intensive treatment of myelodysplastic syndromes and autologous bone marrow transplantation in acute myeloid leukemia (AML) (1993) (0)
A New Prognostic Disease Specific Model To Predict Survival after Intensive Antileukemic Treatment for Young Patients with Poor-Risk MDS and AML: Results of the CRIANT and AML-10 Studies Conducted by the EORTC/GIMEMA/SAKK/HOVON/EBMT Groups. (2004) (0)
Diversity of HLA Class I and Class II Restricted Minor Histocompatibility Antigens in Graft-Versus-Leukemia Reactivity. (2009) (0)
Complete Remission of Immunocytoma without Graft Versus Host Disease Caused by Allo-HLA-DP Specific T Cells. (2006) (0)
EORTC Leukemia Group achievements (2012) (0)
Anti-LFA-1 blocking antibodies prevent the interleukin-8-induced mobilization of hematopoietic progenitor cells (HPC) in rhesus monkeys (1997) (0)
High-Dose Therapy in AL Amyloidosis (2008) (0)
Extracellular Domains of CD8a and β Subunits Are Required and Sufficient for HLA Class I Restricted Helper Activity of TCR-Engineered CD4+ T Cells. (2009) (0)
Potent Alloreactive Effector T Cells Cause Limited Damage to Non-Hematopoietic Tissues Under Non-Inflammatory Conditions, Despite Proper Expression of the Relevant Target Antigens. (2009) (0)
MTS24 expression delineates a population of murine hair follicle keratinocytes with stem cell characteristics (2005) (0)
Influence of hematopoietic growth factors on bone marrow growth (1994) (0)
Leukemia-Reactive Virus-Specific T Cells Generated by T Cell Receptor (TCR) Transfer Preserve Their Dual Specificity upon Repetitive Stimulation of the Endogenous TCR. (2006) (0)
patients with resistant acute myeloid leukemia High incidence of alternatively spliced forms of deoxycytidine kinase in (2013) (0)
Growth Inhibition ofClonogenicLeukemicPrecursor Cellsby Minor Histocompatibility Antigen-specific CytotoxicT Lymphocytes (1991) (0)
Primary cutaneous marginal zone B-cell lymphoma with secondary anetoderma in a patient with Sjögren’s syndrome (2006) (0)
The constant domain of IgG is a possible target antigen for immunotherapy of B cell malignancies in HLA-A1 mismatched transplantation (2001) (0)
The Functional Activity of Genetically Engineered T Cell Receptor Transferred T Cells Is Highly Dependent on Pairing Properties of the Transferred TCR α and β Chains. (2004) (0)
TCR gamma delta+ cells expressing Vgamma 9V delta2, which normally predominate the blood, are found in the spleens of patients with hairy cell leukemia. (1997) (0)
TCA and MLCs in Bone Marrow Transplant Patients (1989) (0)
Successful Generation of Mature Professional Acute Myeloid Leukemia (AML) – Antigen Presenting Cells (APC) Does Not Predict Successful Induction of AML Reactive T Cells for Adoptive Immunotherapy. (2005) (0)
The PROCLIPI study; a prototype registry for rare disease with global collaboration for establishment of a prognostic index in mycosis fungoides and Sezary syndrome (2018) (0)
The impact of post-remission therapy on outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy with or without stem cell transplantation in a joint study (2004) (0)
Prognostic impact of cytogenetics in untreated AML patients aged 16-60 years: preliminary results of the randomized AML-10 phase III trial of the EORTC and GIMEMA Leukemia Groups (2001) (0)
Targeting Of HLA Class II Restricted Antigens In Graft Versus Leukemia Reactivity (2009) (0)
Questions on Hematopoietlc Stem Cells and AML (2003) (0)
Primary Allogeneic T-Cell Responses Against In Vitro Modified Mantle Cell Lymphoma (MCL) Cells: Implications for Adoptive Immunotherapy after HLA-Matched Stem Cell Transplantation (SCT). (2004) (0)
What Is the Relationship Between Lymphomatoid Papulosis and Hodgkin's Disease and Mycosis Fungoides? (1997) (0)
Development of a standard operating procedure for the production of leukemia-reactive T cells under GMP conditions for cellular immunotherapy (2005) (0)
Prediction of response of acute non-lymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside. (1984) (0)
Generation of Combined CD8+ and CD4+ T Cell Lines with High Specificity for Adenovirus Hexon Epitopes for Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation. (2008) (0)
GM-CSF and IL-3 in Myelodysplastic Svndromes at Low Risk of Develoointz (1992) (0)
First Line Treatment of Aggressive Cutaneous NK/T Cell Lymphomas Based on High Dose Cytarabine and Stem Cell Transplantation Does Not Lead to Durable Remissions. (2006) (0)
Cytotoxic T cells induce target cell death via an MHC-restricted granule-mediated and a non MHC- restricted death-receptor-mediated mechanism of killing (2008) (0)
ATP Dependent Interferon Responsive (ADIR) Gene Encodes an Activation Induced Minor Histocompatibility Antigen Recognized on Multiple Myeloma by CD8+ T Cells. (2006) (0)
PrimaryAllogeneic T-Cell Responses againstMantle Cell Lymphoma Antigen-Presenting Cells forAdoptive Immunotherapy after StemCellTransplantation (2005) (0)
Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by (2013) (0)
Collateral Damage: a Mechanism for Hematopoiesis-Restricted Mhag-Specific T Cells to Play a Role in the Effector Phase of GvHD. (2009) (0)
Alemtuzumab as remission induction for adult patients with acute lymphoblastic leukemia in relapse (2005) (0)
Validation of diagnostic and prognostic biomarkers for Sézary syndrome and erythrodermic cutaneous T-cell lymphoma (2010) (0)
Detailed Analysis of CD8+ T Cell Immunity and Identification of a Novel Minor Histocompatibility Antigen Contributing to Graft-Versus- Leukemia Reactivity. (2008) (0)
Stimulatory and Inhibitory Interactions of Granulocyte-Macrophage Colony-Stimulating Factor with Other Cytokines1 (1993) (0)
Disease-specific prognostic factors for outcome of patients with poor-risk Myelodysplastic syndromes (MDS) and acute myeloid leukemia, treated with intensive antileukemic therapy (2003) (0)
Physiological TCR Modulation after Antigen Specific Triggering of Introduced TCRs under Control of a Retroviral Promotor. (2005) (0)
Optimization of the HA-1-specific T-cell receptor for gene therapy of haematological malignancies after stem cell transplantation (2010) (0)
Clinical, histological and molecular characteristics of ALK-positive primary cutaneous anaplastic large cell lymphoma (2019) (0)
Allo-HLA Reactive CD8 T-Cells May Recognize Tissue Specific Peptides Explaining Tissue Restricted GVHD after HLA Mismatched SCT. (2007) (0)
thrombopoietin pretreated donor mice syngeneic transplantation of bone marrow cells derived from Accelerated reconstitution of platelets and erythrocytes after (2011) (0)
mobilization of the intestinal flora: involvement of endotoxins as cofactors in Reduced stem cell mobilization in mice receiving antibiotic modulation (2013) (0)
Immunomodulatory and graft-supportive properties of mesenchymal precursor cells: potential for clinical application in stem cell transplantation (2008) (0)
Physiological Non-Responsiveness and Absence of Activation Induced Cell Death of T Cells Rapidly Re-Expressing Retrovirally Introduced TCRs after T Cell Activation. (2007) (0)
Update Mycosis Fungoides 2011 (2011) (0)
Generation of GMP-Grade CMV pp65-Specific CD8+ and CD4+ Donor T Cell Lines for Treatment of CMV Reactivation after Transplantation. (2006) (0)
Characterization of Late-Appearing Mixed Colonies with High Proliferative Potential from Umbilical Cord Blood (1993) (0)
338: T Cell Receptor Gene Transfer to Virus-Specific T Cells for Cellular Anti-Tumor Immunotherapy (2008) (0)
Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study (2016) (0)
The impact of anthracyclines on feasibility of subsequent autologous or allogeneic transplantation and induced marrow toxicity: interim results of the EORTC - GIMEMA AML-10 trial (2001) (0)
Identification of Four New HLA Class II Restricted Minor Histocompatibility Antigens Contributing to Graft Versus Leukemia Reactivity. (2008) (0)
Intensive Chemotherapy Followed by Stem Cell Transplantation for the Treatment of Myelodysplastic Syndromes (2001) (0)
Poor-Risk Acute Leukemia Patients with An EBMT Low-Risk Score and An 8/8 Matched Unrelated Donor Show Excellent Survival After Hematopoietic Stem Cell Transplantation. (2009) (0)
The role of stromal-derived factor-1 and its receptor CXCR4 in hematopoietic stem cell mobilization (2002) (0)
Myeloid Chimerism Reflects Engraftment of Donor Hematopoiesis, Whereas T Cell Chimerism Reflects Survival and Expansion of Donor and Recipient Residual Mature T Cells Early After T Cell Depleted Allogeneic Stem Cell Transplantation. (2009) (0)
Allogeneic cellular immunotherapy of chronic lymphocytic leukemia (2005) (0)
TCR-CD3 complex controlled by the intrinsic qualities of the TCR chains within the Efficiency of T-cell receptor expression in dual-specific T cells is (2013) (0)
Leukemic Blasts Acting as Host Antigen Presenting Cells Trigger a Combined CD4 and CD8 Allo-Immune Response Directed against Mismatched HLA Class I (2007) (0)
New prognostic score based on clinical and biologic factors in patients < 56 years with poor-risk MDS and AML treated with intensive treatment (2005) (0)
Cytogenetic characteristics predict outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukaemia Groups (2002) (0)
High Throughput Minor Histocompatibility Antigen Discovery by Whole Genome Association Scanning. (2009) (0)
CD97 Is Differentially Expressed on Murine Hematopoietic Stem Cells and Progenitor Cells. (2005) (0)
Identification of Phosphatidylinositol 4-Kinase Type II β as the First HLA Class II Associated Minor Histocompatibility Antigen Involved in Graft Versus Leukemia Reactivity. (2007) (0)
T Cell Receptor Gene Transfer to Virus-Specific T Cells for Cellular Anti-Tumor Immunotherapy. (2007) (0)
Vaccination with HA-1 peptide in patients showing minimal residual disease or mixed chimerism after allogeneic stem cell transplantation and donor lymphocyte infusion (2008) (0)
Autografting in high risk MDS and sAML (2000) (0)
Treatment of rare patients with a primary cutaneous CD30+ lymphoproliferation developing extracutaneous disease: a retrospective study of 43 patients (2019) (0)
Histopathology of Sèzary syndrome in contrast to other erythrodermic skin diseases. (2013) (0)
Treatment of Older Patients, 40 to 70 Years of Age, with Acute Lymphoblastic Leukemia According to a Chemotherapy Regimen That Includes a Novel Pre-Phase for Rapid Tumor Load Reduction. Results of the Dutch-Belgian HOVON-71 Study (2009) (0)
Role of Consolidation Treatment with Increased Dosages of Cytosine Arabinoside in Patients with Acute Leukemia in First Remission (1989) (0)
Intensive chemotherapy versus autologous or allogeneic stemcell transplantation for the treatment of patients with poor risk MDS and secondary AML-A joint study of the Eortc, Ebmt, Hovon, Swiss, Scandinavian and Gimema leukemia groups: A biomed-2 EU-project. (1999) (0)
interleukin-2 in cancer patients (see comments) interleukin-6 during intravenous administration of high-dose stimulating factor, macrophages colony-stimulating factor, and In vivo production of interleukin-5, granulocyte-macrophage colony- (2013) (0)
VP 16.213 in the Treatment of Acute and Chronic Leukaemias (1984) (0)
Leukemia-Reactive T Cells in Adoptive Immunotherapy for Relapsed Leukemia After Allogeneic Transplantation (2000) (0)
High doses of CD34+ cells from umbilical cord blood, bone marrow and mobilized peripheral blood result in comparable myeloid engraftment in the nod/scid mice (2000) (0)
Methodology of evaluation in EORTC trials including BMT in acute myelogenous leukemia (AML) in first complete remission (CR). EORTC Leukemia Cooperative Group (LCG) and GIMEMA. (1991) (0)
Lymphomatoid papulosis with a NK-cell phenotype (2006) (0)
Leukemic CD52 Negative Subclones Due to Defective Glycophosphatidyl-Innositol Anchoring Are Common in Acute Precursor B Lymphoblastic Leukemia, Escape Alemtuzumab Therapy, but Display Increased Sensitivity to Rituximab Mediated Complement Dependent Cytotoxicity: a Mechanistic Rationale for Antibody (2009) (0)
Enhancement of G-CSF-induced stem cell mobilization by antibodies to the beta2-integrin LFA-1 (1998) (0)
GVHD in HLA-A2 Mismatched Transplantation Caused by a Combined CD8 Response Directed Against HLA-A2 and a CD4 Response Recognizing an HLA-A2 Derived Peptide in HLA-DR1. (2006) (0)
Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials (2016) (0)
Donor T-Cells Specific for Lineage-Restricted Maturation Antigens Not Recognizing Immature Progenitor Cells May Lead to Hematologic Remission but Molecular Persistence of Chronic Myeloid Leukemia (CML). (2004) (0)
Abstracts of oral presentations (2005) (0)
49 The influence of cytogenetic abnormalities on treatment outcome after intensive antileukemic therapy for patients with high risk MDS (1997) (0)
176 The Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) Study identifies clinical prognostic markers and establishes the foundation for large-scale translational research in cutaneous lymphoma (2019) (0)
Both the Activation Kinetics and the Frequency of Regulatory T Cells Determine the Ability to Generate Primary Anti-Tumor and Pathogen- Specific Immune Responses from a Naïve Donor T Cell Repertoire (2008) (0)
The susceptibility of trichophyton rubrum to photodynamic treatment (2005) (0)
Combined CDS-positive and CD4-positive adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection (2012) (0)
CNS-Leukaemia Prophylaxis in Adult Acute Lymphoblastic Leukaemia (1980) (0)
Retroviral Interference with Execution Pathways in Target Cells To Unravel Mechanisms of Cytotoxic T Cell-Mediated Cell Death. (2004) (0)
[Ophthalmological side effects of the use of cytostatic agents]. (1985) (0)
The impact of cytogenetic features and clonality on the prognosis of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation: A joint study of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups (2000) (0)
High Avidity HLA-A2-Restricted CD8+ T Cells against the Wilms Tumor Protein (WT1) Can Be Isolated Only from HLA-A2 Negative Donors Not Subjected to HLA-A2-Mediated Thymic Deletion (2008) (0)
Minor histocompatibility antigen HA-1 peptide vaccination to induce graft versus tumor responses after allogeneic stem cell transplantation (2007) (0)
Determination of clonality in myelodysplasia by polymerase chain reaction (1991) (0)
Stem cell transplantation and immunotherapy of hematological diseases (2002) (0)
Universal CD137 Expression upon Activation Allows Efficient Isolation of a Broad Repertoire of Virus-Specific CD8+ and CD4+ T Cells for Adoptive Immunotherapy. (2008) (0)
Persistent clonal excess with skewed TCR V-beta repertoire in blood- and spleen-derived T cells in hairy cell leukemia (1995) (0)
Alpha-1 Antitrypsin Is a Potent Inhibitor of Cytokine-Induced Hematopoietic Stem Cell Mobilization. (2004) (0)
Allogeneic transplantation for adult acute lymphoblastic leukemia: Intention to treat analysis of the EORTC ALL-4 phase III trial (2006) (0)
Poor Outcome after Allogeneic Hematopoietic Stem Cell Transplantation for De Novo AML with Chromosome 7 Abnormalities: A Report for the ALWP of the European Group for Blood and Marrow Transplantation. (2007) (0)
282: Efficient Induction and Isolation of a Primary CMV-specific CD8+ T Cell Response from CMV Seronegative Donors for the Treatment of Serious CMV-Related Complications in CMV Seropositive Patients Transplanted with a CMV Seronegative Donor (2008) (0)
The prognostic impact of cytogenetic features and clonality of patients with poor risk MDS and secondary AML (sAML) after treatment with intensive chemotherapy and stem cell transplantation for the treatment: a joint study oft he EORTCS, EBMT, SAK, HOVO (2001) (0)
- d-Arabinofuranosylcytosine-resistant Leukemic Cells β Substrate-specific Deoxycytidine Kinase Deficiency in 1-Updated Version (2006) (0)
Reduced Risk of the Development of Chronic Myeloid Leukemia HLA-B8 and HLA-A3 Coexpressed With HLA-B8 Are Associated With a (2013) (0)
Profound T Cell Depletion Does Not Eradicate CMV Specific CD8 T Cells Responsible for Protective Immunity to CMV after T Cell Depleted Allogeneic Stem Cell Transplantation. (2006) (0)
Progenitor Cells Induced by Interleukin-8 LFA-1 Blocking Antibodies Prevent Mobilization of Hematopoietic - Anti (2013) (0)
Mechanisms of Acquired ARA-C and DAC Resistance in Acute Myeloid Leukemia (AML): Development of a Model for the Study of Mutational Loss of Deoxycytidine Kinase (DCK) Activity (1996) (0)
Cytomegalovirus-Specific CD 8 Receptor-Expressing Functional Analysis of Killer Ig-Like Falkenburg (2008) (0)
Long‐term engraftment of mice transplanted with interleukin‐1 primed blood‐derived The International Journal of Cell Cloning (1992) (0)
The Prognostic Relevance of Leukemic Cell Typing in Acute Lymphoblastic Leukemia (1980) (0)
Proceedings of the 247th Meeting of the Netherlands Society for Dermatology and Venereology, Free University, Amsterdam, 27 January 1990 (1990) (0)
Characterization of T cell specificities responsible for differential GVHD and anti-tumor-reactivity induced by donor lymphocyte infusion (2006) (0)
Human B cell colony assays (1987) (0)
Prognostic F actors i n P rimary C utaneous L arge B -Cell Lymphomas: A E uropean M ulticenter S tudy (2001) (0)
Sixteenth annual meeting of the european cooperative group for bone marrow transplantation the hague netherlands may 6 9 1990 (1990) (0)
Human cellular immunotherapy of human hematological malignancies studied in NOD/SCID mice (2000) (0)
[Bone marrow transplantation and (or) immunosuppression with antithymocyte globulin in the treatment of aplastic anemia]. (1978) (0)
granulocyte colony-stimulating factor factor on granulocytic colony formation by intermediate production of Interleukin-1 synergizes with granulocyte-macrophage colony-stimulating (2013) (0)
Value of allogeneic stem cell transplantation (SCT) versus autologous SCT and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial (2010) (0)
KIR-Ligand Incompatibility in the Graft-Versus-Host Direction Is Associated with Better Outcomes after Unrelated Cord Blood Stem Cell Transplantation for Acute Leukemia in Complete Remission (2008) (0)
High dose cytosine arabinoside (HDAra-C) induces recruitment and synchronization of the leukemic cells and not of the normal haemopoietic stemcells; studies in the BNML (1986) (0)
Re-Engineering γ δ T Cells by α β T Cell Receptor Gene Transfer Creates Potent Effector Cells with Anti-Leukemic Reactivity. (2005) (0)
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013) (2015) (0)
MOLECULAR ANALYSIS OF PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA LEG TYPE AT DIAGNOSIS AND RELAPSE - IMPLICATIONS FOR TARGETED THERAPIES (2019) (0)
Engineered antigen-presenting leukemic cells for cellular immunotherapy of acute lymphoblastic leukemia (2004) (0)
Vesicular mycosis fungoides (2006) (0)
Focal Deletion of Genes Involved in the Control of Cell Cycle Progression Contributes to Growth Factor Independence in Acute Lymphoblastic Leukemia Cells (2008) (0)
The role of neutrophils in hematopoietic stem cell mobilization. (1999) (0)
Myeloablative T-cell depleted allogeneic stem cell transplantation with early sequential prophylactic donor lymphocyte infusion for adult acute lymphoblastic leukaemia in first complete remission (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Roelof Willemze?

Roelof Willemze is affiliated with the following schools:

Roelof Willemze's Academic­Influence.com Rankings

Roelof Willemze's Degrees

Why Is Roelof Willemze Influential?

Roelof Willemze's Published Works

Published Works

What Schools Are Affiliated With Roelof Willemze?

Roelof Willemze's AcademicInfluence.com Rankings